Transcatheter Aortic Valve Implantation And Surgical Aortic Valve Replacement Among Hospitalized Patients With And Without Type 2 Diabetes Mellitus In Spain (2014-2015) by Mendez Bailon, Manuel et al.
Mendez‑Bailon et al. Cardiovasc Diabetol  (2017) 16:144 
DOI 10.1186/s12933‑017‑0631‑6
ORIGINAL INVESTIGATION
Transcatheter aortic valve implantation 
and surgical aortic valve replacement 
among hospitalized patients with and 
without type 2 diabetes mellitus in Spain (2014–
2015)
Manuel Mendez‑Bailon1, Noel Lorenzo‑Villalba2, Nuria Muñoz‑Rivas3, Jose Maria de Miguel‑Yanes4, 
Javier De Miguel‑Diez5, Josep Comín‑Colet6, Valentin Hernandez‑Barrera7, Rodrigo Jimenez‑Garcia7* 
and Ana Lopez‑de‑Andres7
Abstract 
Background: Type 2 diabetes mellitus (T2DM) is strongly related to the in‑hospital and short‑term prognosis in 
patients with cardiovascular diseases needing surgical or invasive interventions. How T2DM might influence the 
treatment of aortic stenosis (AS) has not been completely elucidated for surgical aortic valve replacement (SAVR) 
or transcatheter aortic valve implantation (TAVI). The aims of this study were: (1) to describe the use of aortic valve 
replacement procedures (TAVI and SAVR) among hospitalized patients with and without T2DM; and (2) to identify fac‑
tors associated with in hospital mortality (IHM) among patients undergoing these procedures.
Methods: We analyzed data from the Spanish National Hospital Discharge Database between January 1, 2014 and 
December 31, 2015 for patients aged ≥ 40 years. We selected patients whose medical procedures included TAVI (ICD‑
9‑CM codes 35.05, 35.06) and SAVR (ICD‑9‑CM codes 35.21, 35.22). We stratified each cohort by diabetes status: T2DM 
(ICD‑9‑CM codes 250.x0, 250.x2) and no diabetes. We retrieved data about specific comorbidities, risk factors, proce‑
dures, and specific in‑hospital postoperative complications. Hospital outcome variables included IHM, and length of 
hospital stay (LOHS).
Results: We identified a total of 2141 and 16,013 patients who underwent TAVI (n = 715; 33.39% with T2DM) and 
SAVR (n = 4057; 25.33% with T2DM). In patients who underwent TAVI we found no differences in IHM (3.64% in T2DM 
vs. 5.12% in non‑T2DM, p = 0.603). In the cohort of SAVR, mean LOHS was significantly lower in patients with T2DM 
than in non‑diabetic patients (13.77 vs. 17.27 days). IHM was lower in patients with T2DM (4.36% vs. 6.31%, p < 0.01). 
After multivariable adjustment for both procedures, patients with T2DM had significantly lower IHM than patients 
without diabetes (adjusted OR 0.60; IC 95% 0.37–0.99 for TAVI and adjusted OR 0.80; IC 95% 0.66‑0‑96 for SAVR).
Conclusions: T2DM diabetic patients with AS undergoing a valvular replacement procedure through SAVR or TAVI 
did not have a worse prognosis compared to non‑diabetic patients during hospitalization, showing lower IHM after 
multivariable adjustment. However, given the limitations of administrative data more prospective studies and clinical 
trials aimed at evaluating the influence of these procedures in diabetic patients with AS are needed.
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Background
Type 2 diabetes mellitus (T2DM) is associated with a 
wide range of complications and higher risk of cardiovas-
cular death worldwide [1]. Valvular heart disease, in par-
ticular is more common in diabetes [2].
Aortic stenosis (AS) is a degenerative valvular disease 
more related to advance age and the presence of cardi-
ovascular risk factors [3]. In recent studies, such as the 
CANHEART aortic stenosis study, T2DM was found to 
be second only to hypertension as the medical condi-
tion most associated with aortic stenosis in a population 
of 1.12 million individuals followed prospectively over 
13 years [4].
The association between T2DM and AS is due to the 
increased development of atherosclerosis in diabetic 
patients [5]. The activation of the rennin-angiotensin-
aldosterone axis, elevation of inflammatory interleukins, 
production of free radicals, and glycosylation of proteins 
lead to an increase in profibrotic and calcific processes 
causing aortic valvular calcification and progression to 
AS [5, 6].
With the aging of the population, the incidence and 
prevalence of AS are expected to increase [7]. AS is pres-
ently the most common valvular condition leading to val-
vular replacement [6]. AS has been classically managed 
with surgical aortic valve replacement (SAVR), but this 
has changed recently as less invasive procedures such 
as transcatheter aortic valve implantation (TAVI) have 
become available [6–8]. This procedure is currently con-
sidered to be the procedure of choice in the treatment 
of patients with AS and high surgical risk, especially in 
elderly individuals [6]. However, clinical trials evaluating 
the therapeutic role of TAVI in patients at intermediate 
surgical risk have shown non-inferiority between TAVI 
and SAVR in the primary endpoint [8, 9].
Type 2 Diabetes mellitus is strongly related to the 
in-hospital and short-term prognosis in patients with 
cardiovascular diseases needing surgical or invasive 
interventions [10, 11]. How T2DM might influence the 
treatment of AS has not been completely elucidated for 
SAVR or TAVI [9, 12–14]. In addition, the conflicting 
results of published clinical trials and multicenter studies 
led to the current research.
The aims of this study were: (1) to describe the use 
of aortic valve replacement procedures (TAVI and 
SAVR) among hospitalized patients with and without 
T2DM; and (2) to identify factors associated with in 
hospital mortality (IHM) among patients undergoing 
these procedures.
Methods
We analyzed data from the Spanish National Hospital 
Discharge Database (SNHDD), between January 1, 2014 
and December 31, 2015 for patients aged 40  years and 
over. This database covers more than 98% of Spanish 
hospital admissions and includes patient’s sex and date 
of birth, admission and discharge dates, diagnoses at dis-
charge (up to 14), and procedures (up to 20) performed 
during the hospital stay [15].
We selected patients whose medical procedures 
included TAVI [International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes 
35.05, 35.06] and SAVR (ICD-9-CM codes 35.21, 35.22). 
TAVI codes were included in the SNHDD in year 2014. If 
a patient had both procedures was excluded. Also those 
with other cardiac surgery procedures were excluded.
We stratified each cohort by diabetes status: T2DM 
(ICD-9-CM codes 250.x0, 250.x2) and no diabetes.
Clinical characteristics included information on over-
all comorbidities at the time of diagnosis, assessed by 
calculating the Charlson comorbidity index (CCI) [16]. 
The CCI was calculated excluding DM as a disease. We 
retrieved data about specific comorbidities, risk factors, 
procedures, and specific in-hospital postoperative com-
plications. The conditions studied and the codes used to 
identify them according to the ICD-9-CM are shown in 
Additional file 1: Table S1.
We created a new variable “Any post procedure com-
plication” that includes those patients who suffered infec-
tion and/or mediastinitis and/or functional disturbances 
following SAVR or TAVI.
Hospital outcome variables included in-hospital mor-
tality (IHM) length of hospital stay (LOHS) and costs. 
IHM was defined as the proportion of patients who died 
during the admission.
Statistical analysis
A descriptive statistical analysis was performed. Variables 
are expressed as proportions or as means with standards 
deviations (SDs). We compared specific comorbidities, 
risk factors, procedures, specific in-hospital postopera-
tive complications, and in-hospital outcomes between 
T2DM patients and noT2DM patients in the TAVI cohort 
and in SAVR cohort. To compare continuous variables, 
Keywords: Type 2 diabetes, Transcatheter aortic valve implantation, Surgical aortic valve replacement, Hospital, 
Mortality
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we used the Student’s T test and Chi square test for 
proportions.
We performed two unconditional logistic regression 
analyses to identify the variables associated to in-hos-
pital mortality as a binary outcome among all patients 
who underwent TAVI and SAVR. The variables included 
in the models were those with significant results in the 
bivariate analysis and those considered relevant in other 
investigations (obesity).
We also conducted two logistic regression models 
using “Any post procedure complication” as dependent 
variables to assess the effect of DM after controlling for 
other variables.
Estimates were expressed as odds ratios (OR) with their 
95% confidence intervals.
All statistical analyses were performed using Stata ver-
sion 10.1 (Stata, College Station, Texas, USA). Statistical 
significance was set at p < 0.05 (2-tailed).
Ethical aspects
Data confidentiality was maintained at all times in 
accordance with Spanish legislation. Given the anony-
mous and mandatory nature of the dataset, it was not 
deemed necessary to obtain informed consent nor an 
ethics committee approval.
Results
In 2014/15, we identified a total of 2141 and 16,013 
patients who underwent TAVI (n  =  715; 33.39% with 
T2DM) and SAVR (n = 4057; 25.33% with T2DM).
Table  1 shows the characteristics of hospital admis-
sion for patients who underwent the TAVI procedure in 
Spain, 2014/15. In our study, we found that 46.71% were 
women with diabetes compared with 52.66% without dia-
betes (p = 0.009). Patients with T2DM were significantly 
younger than those without diabetes (79.52  years vs. 
81.36 years, respectively).
Diabetic patients who underwent a TAVI procedure 
had higher CCI mean values compared to those with-
out T2DM (1.22 vs. 1.03, respectively; p < 0.01). Among 
patients with T2DM, the most common comorbidities 
according to the CCI included chronic pulmonary dis-
eases (29.09%), congestive heart failure (28.53%), and 
renal disease (27.27%). Renal disease was significantly 
more frequent in patients with diabetes than in those 
without diabetes, as can been seen in Table 1.
Patients with T2DM had a higher incidence of ischemic 
heart disease (43.92% vs. 33.52%, p  <  0.01), hyperten-
sion (60.42% vs. 50.63%, p < 0.01), lipid metabolism dis-
orders (50.77% vs. 35.69%, p < 0.01), and obesity (17.2% 
vs. 7.78%, p < 0.01) than those without diabetes (Table 1). 
Atrial fibrillation was less prevalent among T2DM 
(30.91% vs. 35.62%; p = 0.030).
Table 1 Characteristics, comorbidities, risk factors, proce-
dures, postoperative complications and  in-hospital out-
comes in  patients underwent TAVI in  Spain in  2014/15, 
according to type 2 diabetes status
a CCI was calculated excluding DM
b Any post procedure complication included: infection; mediastinitis; and 






Female sex, n (%) 334 (46.71) 751 (52.66) 0.009
Age, mean (SD) 79.52 (6.27) 81.36 (6.71) < 0.01
Age groups, n (%)
 40–79 years 298 (41.68) 401 (28.12) < 0.01
 80–84 years 281 (39.3) 538 (37.73)
 ≥ 85 years 136 (19.02) 487 (34.15)
Charlson comorbidity index, 
mean (SD)a
1.22 (1) 1.03 (0.96) < 0.01
Congestive heart failure, n (%) 204 (28.53) 374 (26.23) 0.257
Cerebrovascular disease, n (%) 46 (6.43) 73 (5.12) 0.211
Dementia, n (%) 5 (0.7) 6 (0.42) 0.395
Chronic pulmonary disease, 
n (%)
208 (29.09) 383 (26.86) 0.276
Renal disease, n (%) 195 (27.27) 269 (18.86) < 0.01
Ischemic heart disease, n (%) 314 (43.92) 478 (33.52) < 0.01
Atrial fibrillation, n (%) 221 (30.91) 508 (35.62) 0.030
Intermittent claudication, n (%) 12 (1.68) 28 (1.96) 0.646
Endocarditis, n (%) 1 (0.14) 1 (0.07) 0.618
Hypertension, n (%) 432 (60.42) 722 (50.63) < 0.01
Lipid metabolism disorders, 
n (%)
363 (50.77) 509 (35.69) < 0.01
Smoking, n (%) 130 (18.18) 213 (14.94) 0.054
Obesity, n (%) 123 (17.2) 111 (7.78) < 0.01
Catheterization, n (%) 112 (15.66) 228 (15.99) 0.846
Computerized tomography of 
the torax, n (%)
51 (7.13) 104 (7.29) 0.893
Magnetic resonance imaging, 
n (%)
1 (0.14) 4 (0.28) 0.525
Pacemaker device implantation, 
n (%)
100 (13.99) 214 (15.01) 0.529
Cardioversion, n (%) 14 (1.96) 35 (2.45) 0.469
Balloon counterpulsation, n (%) 3 (0.42) 10 (0.7) 0.429
Percutaneous coronary inter‑
ventions
30 (4.20) 66 (4.63) 0.648
Hemodialysis, n (%) 20 (2.8) 30 (2.1) 0.316
Red blood cell transfusion, n (%) 120 (16.78) 215 (15.08) 0.305
Infection, n (%) 13 (1.82) 35 (2.45) 0.348
Mediastinitis, n (%) 0 (0) 1 (0.07) 0.479
Functional disturbances  
following TAVI, n (%)
6 (0.84) 15 (1.05) 0.638
Any post procedure 
 complicationb
19 (2.66) 49 (3.44) 0.332
Mortality, n (%) 26 (3.64) 73 (5.12) 0.123
Length of stay, mean (SD) 12.54 (11.43) 12.83 (12.07) 0.603
Cost, mean (SD) 20,356 (8897) 20,983 (9623) 0.145
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In patients who underwent TAVI, red blood cell trans-
fusion, catheterization, and pacemaker device implanta-
tion were the most frequent procedures. We found no 
differences in IHM (3.64% in T2DM patients vs. 5.12% in 
non-T2DM patients, p = 0.603).
The characteristics, comorbidities, risk factors, pro-
cedures, postoperative complications, and in-hospital 
outcomes in patients with and without diabetes who 
underwent SAVR are shown in Table 2.
Patients withT2DM were significantly older 
(72.47 ± 7.76 years vs. 70.36 ± 10.03 years, p < 0.01) and 
had higher frequencies of comorbidities according to 
the CCI (0.83 ± 0.9 vs. 0.81 ± 0.88, p < 0.01) than non-
diabetic patients. Renal disease was significantly more 
Table 2 Characteristics, comorbidities, risk factors, procedures, postoperative complications and  in-hospital outcomes 
in patients underwent SAVR in Spain in 2014/15, according to type 2 diabetes status
a CCI was calculated excluding DM






Female sex, n (%) 1630 (40.18) 5061 (42.33) 0.016
Age, mean (SD) 72.47 (7.76) 70.36 (10.03) < 0.01
Age groups, n (%)
 40–66 years 828 (20.41) 3562 (29.79) < 0.01
 67–75 years 1591 (39.22) 3961 (33.13)
 ≥ 76 years 1638 (40.37) 4433 (37.08)
Charlson comorbidity index, mean (SD)a 0.83 (0.9) 0.81 (0.88) < 0.01
Congestive heart failure, n (%) 711 (17.53) 2229 (18.64) 0.112
Cerebrovascular disease, n (%) 284 (7) 682 (5.7) 0.003
Dementia, n (%) 13 (0.32) 17 (0.14) 0.023
Chronic pulmonary disease, n (%) 798 (19.67) 2295 (19.2) 0.508
Renal disease, n (%) 571 (14.07) 1085 (9.07) < 0.01
Ischemic heart disease, n (%) 1626 (40.08) 3470 (29.02) < 0.01
Atrial fibrillation, n (%) 1523 (37.54) 4778 (39.96) 0.006
Intermittent claudication, n (%) 67 (1.65) 80 (0.67) < 0.01
Endocarditis, n (%) 128 (3.16) 549 (4.59) < 0.01
Hypertension, n (%) 2731 (67.32) 6094 (50.97) < 0.01
Lipid metabolism disorders, n (%) 1856 (45.75) 3447 (28.83) < 0.01
Smoking, n (%) 1041 (25.66) 2920 (24.42) 0.115
Obesity, n (%) 729 (17.97) 1200 (10.04) < 0.01
Catheterization, n (%) 523 (12.89) 1302 (10.89) 0.001
Computerized tomography of the torax, n (%) 149 (3.67) 629 (5.26) < 0.01
Magnetic resonance imaging, n (%) 13 (0.32) 45 (0.38) 0.608
Pacemaker device implantation, n (%) 194 (4.78) 551 (4.61) 0.651
Cardioversion, n (%) 205 (5.05) 749 (6.26) 0.005
Balloon counterpulsation, n (%) 55 (1.36) 275 (2.3) < 0.01
Percutaneous coronary interventions 41 (1.01) 70 (0.59) 0.005
Hemodialysis, n (%) 127 (3.13) 435 (3.64) 0.129
Red blood cell transfusion, n (%) 941 (23.19) 2806 (23.47) 0.721
Infection, n (%) 148 (3.65) 554 (4.63) 0.008
Mediastinitis, n (%) 10 (0.25) 46 (0.38) 0.197
Functional disturbances following SAVR, n (%) 22 (0.54) 101 (0.84) 0.057
Any post procedure  complicationb 170 (4.19) 659 (5.51) 0.001
Mortality, n (%) 177 (4.36) 754 (6.31) < 0.01
Length of stay, mean (SD) 16.37 (13.77) 17.54 (17.27) < 0.01
Cost, mean (SD) 23,667 (11,994) 24,659 (15,210) < 0.001
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common in patients with diabetes (14.07%) than in those 
without diabetes (9.07%).
Hypertension (67.32% vs. 50.97%, p  <  0.01), lipid 
metabolism disorders (45.75% vs. 28.83%, p  <  0.01), 
ischemic heart disease (40.08% vs. 29.02%, p < 0.01), obe-
sity (17.97% vs. 10.04%, p < 0.01), and intermittent clau-
dication (1.65% vs. 0.67%, p  <  0.01) were significantly 
more prevalent in diabetic patients than in those without 
T2DM. However diabetic patients had a lower frequency 
of atrial fibrillation (37.54% vs. 39.96%, p =  0.006) and 
endocarditis (3.16% vs. 4.59%, p < 0.01) than non-T2DM 
patients (Table 2).
Catheterization rate and percutaneous coronary inter-
ventions were significantly higher in diabetic patients 
than in those without diabetes (12.89% vs. 10.89% and 
1.01% vs. 0.59% respectively). However, computerized 
tomography of the thorax and balloon counterpulsation 
were significantly more frequent in non-T2DM patients 
than in diabetic patients, as can been seen in Table  2. 
Also postoperative infection (3.65% vs. 4.63%, p = 0.008) 
was lower in diabetic patients than in the non-T2DM 
group. The prevalence of “Any post procedure complica-
tion” was significantly higher among those without than 
with T2DM (5.51% vs. 4.19%; p = 0.001).
In the cohort of SAVR, mean LOHS was significantly 
lower in patients with T2DM than in non-diabetic 
patients (13.77 days vs. 17.27 days). As expected this was 
associated to a lower cost among T2DM patients (23,667 
vs. 24,659 Euros; p < 0.001).
In hospital mortality was significantly lower in patients 
with T2DM (4.36% vs. 6.31%, p < 0.01) than in non-dia-
betic patients.
Table 3 shows the result of logistic regression analyses 
to assess the factors associated with IHM in all patients 
during hospital admission for TAVI and SAVR proce-
dures. Comorbidities, computerized tomography of the 
thorax, cardioversion, hemodialysis, and red blood cell 
transfusion increased the risk of IHM in patients who 
underwent TAVI and SAVR.
Among patients who underwent SAVR, endocarditis, 
balloon counterpulsation, and postoperative infection 
were associated with higher IHM. However, patients 
with atrial fibrillation, hypertension, lipid metabolism 
disorders, smoking, pacemaker device implantation, and 
higher LOHS had lower risk of IHM.
For both procedures, patients with T2DM had sig-
nificantly lower mortality than patients without diabe-
tes (adjusted OR 0.60; IC 95% 0.37–0.99 for TAVI and 
adjusted OR 0.80; IC 95% 0.66-0-96 for SAVR).
The results of the multivariable logistic regression 
showed no significant association of T2DM with suf-
fering “Any post procedure complication” with adjusted 
OR’s of 0.80 (95% CI 0.45–1.44) for TAVI and 0.87 (95% 
CI 0.72–1.04) for SAVR (see Additional file 1: Table S2).
Discussion
This study showed that T2DM does not increase in-
hospital mortality in patients with AS requiring valvular 
replacement either through open surgery or transcath-
eter aortic valve implantation. Outcomes with TAVI in 
T2DM are conflicting in published reports [17, 18]. In a 
recent subanalysis, of the clinical trial PARTNER (Place-
ment of Aortic Transcatheter Valves), mortality at 1 year 
follow up was higher in non-T2DM individuals [19]. 
However, a German registry showed that T2DM patients 
receiving TAVI had a worse prognosis with increase mor-
tality in the short and long terms [20].
In Israel 443 patients (35.6% suffering DM) with severe 
AS undergoing TAVR were followed for 2 years and the 
results of the Kaplan–Meier survival analysis showed that 
DM was not associated with increased mortality [21].
Sun et  al. [22] have published a recent meta-analysis 
showing that T2DM patients did not have an increase in 
mortality 30 days and 1 year after TAVI. A sub-analysis 
of the clinical trial PARTNER also showed a decrease of 
annual mortality in T2DM patients undergoing TAVI 
versus SAVR [19]. According to researchers, this ten-
dency could be the result of the presence of obesity in 
the group of diabetic patients. Many studies have dem-
onstrated obesity to have a protector effect on in-hospital 
mortality [23]. In our study, T2DM patients undergoing 
TAVI were more often obese compared to non diabetic 
patients. However, as can be seen in Table 3, after multi-
variable adjustment obesity was not associated to IHM in 
patients undergoing TAVI or SAVR in our investigation.
In our database, T2DM patients undergoing TAVI 
implantation were younger than the non-diabetic cases. 
The proportion of patients aged 85 years and more was 
significantly lower in the group of T2DM patients under-
going TAVI. This fact might have influenced on the prog-
nostic results of diabetes in the study considering elderly 
patients with diabetes mellitus and established cardiovas-
cular disease have higher mortality [24].
In cases undergoing SAVR, T2DM patients were found 
to have lower mortality than non-diabetic patients. These 
results differ from those reported by other authors who 
have found an increase in mortality in T2DM patients 
who underwent SAVR [14]. Despite an overall lower mor-
tality in patients with DM, those diabetics undergoing 
SAVR had a higher mortality than diabetics undergoing 
TAVI. Ando et  al. [14], in a recent study, demonstrated 
that diabetic patients with aortic stenosis undergoing 
TAVI (n =  5719) had lower in–hospital mortality com-
pared to those undergoing open surgical replacement 
(N = 65,096). The lower in-hospital mortality in T2DM 
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patients undergoing SAVR compared to non-diabetics 
might be multifactorial. Obesity was also more prevalent 
in T2DM patients undergoing SAVR and this might have 
contributed to the decrease of in-hospital mortality as 
previously mentioned [23].
Post-surgery infections and endocarditis were less fre-
quent in T2DM patients undergoing open SAVR. It is 
well known that endocarditis worsens the prognosis after 
valvular intervention [25]. In our series, the multivari-
ate analysis of SAVR cases showed that endocarditis and 
infections were factors independently associated with 
mortality. Of note, balloon counterpulsation was more 
often used in patients without T2DM and undergoing 
open surgery. This procedure is a marker of severity in 
post-surgical care and it is associated with an increase of 
mortality as observed in our study [26].
In our study we found that some results of the regres-
sion analysis for SAVR do not appear to clinically make 
sense including that atrial fibrillation, hypertension and 
smoking, lipid disorder were associated with lower IHM. 
In our opinion the possible explanation for this is a cod-
ing bias. Previous studies have found that people who 
codify may not record risk factors or not very severe 
conditions, such as atrial fibrillation, when other severe 
conditions are present [27, 28]. As a consequence of this 
patients with less severe conditions have risk factor and 
other diseases such as atrial fibrillation over codified. 
This over codification would result in a protective effect 
of these conditions.
The overall IHM in patients undergoing TAVI in our 
study was 4.62%. This figure is much higher than that 
reported by the FORWARD Study (1.9% at 30 days) [29]. 
The use of next-generation, self-expanding Evolut R THV 
and different selection criteria in the FORWARD Study 
may explain the differences [29].
The interpretation of our results, regarding the prog-
nostic impact on survival of diabetes in patients under-
going TAVI or SAVR, may have some limitations. The 
degree of frailty and functional capacity of patients 
undergoing valve implantation was unknown. However, 
it is well known that fragile patients are at higher risk of 
complications after TAVI [30–32]. Gylcated hemoglobin, 
disease course and the antidiabetic treatment received 
are also factors influencing the prognosis after TAVI 
in T2DM patients. In this respect, Conrotto et  al. [33] 
showed that diabetic patients under insulin regime and 
with poor glycemic control had higher mortality after 
TAVI compared to patients receiving oral antidiabetic 
treatment and better glycemic control. However, our 
study is based on an administrative database, so it lacks 
some relevant clinical parameters such as glycemic con-
trol, glycated hemoglobin, treatments during hospitaliza-
tion or left ventricular ejection fraction. Absence of these 
parameters may affect the analysis and limit the general-
izability of this study.
We did not compare TAVI versus SAVR as the clini-
cal characteristics of patients in both groups was quite 
different. Individuals undergoing TAVI were in general 
older and with more comorbities compared to those 
undergoing SAVR. This could be explained from the 
fact that TAVI is mainly indicated in patients at high 
surgical risk in Spain. In a recent report from the Span-
ish National Society of Cardiology (Spain: coronary and 
structural heart interventions from 2010 to 2015) was 
stated that the 73.2% of patients undergoing TAVI were 
not elected for SAVR and were at very high surgical risk 
[34]. Information about surgical risk was not available in 
Table 3 Logistic regression analysis of  the factors associ-
ated with  in-hospital mortality in  all patients who under-
went TAVI and SAVR in Spain, 2014/15
a Charlson comorbidity index was calculated excluding DM
OR (95% CI)
TAVI (n = 2141)
Charlson comorbidity  indexa 1.60 (1.29–1.96)
Diabetes 0.60 (0.37–0.99)
Computerized tomography of the torax 1.85 (1.02–3.54)
Cardioversion 5.30 (2.42–11.60)
Hemodialysis 15.74 (8.08–30.64)
Red blood cell transfusion 1.96 (1.21–3.17)
Obesity 0.95 (0.55–2.26)
SAVR (n = 16,013)
Female sex 1.33 (1.14–1.56)
Age groups (years)
 40–66 1
 67–75 1.57 (1.26–1.96)
 ≥ 76 2.68 (2.17–3.31)
Charlson comorbidity  indexa 1.61 (1.49–1.74)




Lipid metabolism disorders 0.81 (0.68–0.97)
Smoking 0.60 (0.48–0.76)
Computerized tomography of the torax 2.03 (1.57–2.62)
Pacemaker device implantation 0.68 (0.47–0.99)
Cardioversion 1.53 (1.17–2.00)
Balloon counterpulsation 11.11 (8.50–14.52)
Hemodialysis 9.98 (8.02–12.40)
Red blood cell transfusion 1.71 (1.46–1.99)
Postoperative infection 2.28 (1.75–2.97)
Length of stay 0.98 (0.97–0.99)
Obesity 0.92 (0.71–1.20)
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our database but we could infer that most patients under-
going TAVI were at high surgical risk. In future studies, it 
will be of interest to know the prognostic role of diabetes 
in patients at low or intermediate risk undergoing TAVI 
or SAVR.
It must be highlighted that infra-codification of TAVI 
could be possible in our database because this code 
was first introduced in year 2014-despite this, it seems 
that the frequency of TAVI implantation is lower than 
in other European countries [34]. Besides, in diabetic 
patients undergoing TAVI, the type of prosthesis and 
implantation pathway were not analyzed even though we 
know that transfemoral via is the most widely used (85% 
of cases in Spain in 2015) [34].
Unfortunately the SNHDD doesn’t include dates for the 
coded diagnosis. Therefore, it is not possible to know if 
diseases such as myocardial infarction, stroke, vascular 
complications, acute kidney injury among others were 
comorbid conditions present when the patients was 
admitted to the hospital or if appeared as a perioperative 
complication. Unknown differences in the incidence of 
these major complications could explain the lower IHM 
in T2DM patients compared to non-diabetics.
Conclusions
Type 2 diabetes mellitus patients with AS undergoing a 
valvular replacement procedure through SAVR or TAVI 
did not have a worse prognosis compared to non-diabetic 
patients during hospitalization, showing lower IHM after 
multivariable adjustment. However, given the methodo-
logical limitations of administrative data more prospec-
tive studies and clinical trials aimed at evaluating the 
influence of these procedures in diabetic patients with 
AS are needed.
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